Sakar Healthcare Makes Strides in Oncology Product Registration; Stock Jumps 10%

Sakar Healthcare Submits 20 Dossiers Across Multiple Countries

Sakar Healthcare Limited, an ISO 9001:2015 certified pharmaceutical company, has made significant progress in its global expansion efforts. The company announced the submission of 20 dossiers for oncology product registration across various regions, including Switzerland, Bulgaria, Slovenia, Vietnam, Myanmar, and Ethiopia.

Expanding the Anti-Cancer Portfolio

Sakar has developed a range of oncology products in its research-driven, API-integrated EU GMP-approved finished dosage manufacturing units. These units are capable of producing both oral solid dosages and injections. The company has prepared 19 product dossiers in the anti-cancer category for submission to key identified countries worldwide.

Rigorous Development and Testing Process

The company’s in-house technical and regulatory team has been working diligently to ensure the quality and compliance of their products:

1. Oral solid dosages are undergoing bioequivalence studies from EU-approved CROs.
2. Injection products have been tested for bacterial endotoxin (BET) and sterility, following process validations and stability studies.
3. Reference standards used for product development have been procured from Europe.
4. APIs come with a Certificate of Suitability (CEP), making the formulation dossiers compliant with EU and other regulated market regulations.

Potential for Global Market Expansion

Once the registrations or Marketing Authorisations (MA) are received, Sakar Healthcare will have the opportunity to export these high-value products across various regions, including:

• Europe
• The United Kingdom
• South and Central America
• Africa
• Middle East and North Africa (MENA)
• Asia-Pacific (APAC)

Market Response and Stock Performance

The announcement has been well-received by investors, with the company’s stock jumping 10% following the news. The stock also recorded its highest trading volume in four months, indicating increased investor interest. 

However, it’s worth noting that despite this strong move, Sakar Healthcare’s stock is still down by 15% year-to-date in 2024. This suggests that while investors are optimistic about the recent developments, the company may still be facing some challenges in the broader market context.

Looking Ahead

As Sakar Healthcare awaits the results of its registration submissions, the company’s focus on oncology products and global expansion could potentially help to drive the company’s performance.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. The information is based on various secondary sources on the internet and is subject to change. Please consult with a financial expert before making investment decisions.